# James S Novak

List of Publications by Year
in descending order



| 17 | 626 | 758635 12 | 794141 19 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 20 | 20 | 20 | 994 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Human muscle stem cells are refractory to aging. Aging Cell, 2021, 20, e13411. | 3.0 | 18 |
| 2 | Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy. Life, 2021, 11, 827. | 1.1 | 6 |
| 3 | Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy. Journal of Neuromuscular Diseases, 2021, 8, S383-S402. | 1.1 | 13 |
| 4 | Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, 8, S369-S381. | 1.1 | 1 |
| 5 | Anoctamin 5 Knockout Mouse Model Recapitulates LGMD2L Muscle Pathology and Offers Insight Into in vivo Functional Deficits. Journal of Neuromuscular Diseases, 2021, 8, S243-S255. | 1.1 | 5 |
| 6 | Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy. International Journal of Molecular Sciences, 2020, 21, 5575. | 1.8 | 16 |
| 7 | TGF-Î²â€“driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse model. JCI Insight, 2020, 5, . | 2.3 | 87 |
| 8 | Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis. Journal of Pathology, 2019, 249, 215-226. | 2.1 | 24 |
| 9 | Morpholinoâ€induced exon skipping stimulates cellâ€mediated and humoral responses to dystrophin in mdx mice. Journal of Pathology, 2019, 248, 339-351. | 2.1 | 16 |
| 10 | Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD. Molecular Therapy - Nucleic Acids, 2018, 13, 534-542. | 2.3 | 7 |
| 11 | The macrophage as a Trojan horse for antisense oligonucleotide delivery. Expert Opinion on Therapeutic Targets, 2018, 22, 463-466. | 1.5 | 13 |
| 12 | Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle. Nature Communications, 2017, 8, 941. | 5.8 | 44 |
| 13 | Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. Molecular Therapy, 2017, 25, 2561-2572. | 3.7 | 63 |
| 14 | Effect of genetic background on the dystrophic phenotype inmdxmice. Human Molecular Genetics, 2016, 25, 130-145. | 1.4 | 166 |
| 15 | TNF-Î±-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy. Cell Reports, 2015, 12, 1678-1690. | 2.9 | 62 |
| 16 | Elusive sources of variability of dystrophin rescue by exon skipping. Skeletal Muscle, 2015, 5, 44. | 1.9 | 26 |
| 17 | Germline Quality Control: eEF2K Stands Guard to Eliminate Defective Oocytes. Developmental Cell, 2014, 28, 561-572. | 3.1 | 55 |